Skip to main content

Advertisement

Log in

Shionone Relieves Ulcerative Colitis by Regulating the p38 MAPK/NF-κB Pathway

  • Original Article
  • Published:
Revista Brasileira de Farmacognosia Aims and scope Submit manuscript

Abstract

Ulcerative colitis is a serious intestinal disorder, which can lead to a variety of complications, and in severe cases, the risk of becoming cancerous, seriously harming human health. This study aimed to investigate the anti-inflammatory effect of shionone on ulcerative colitis and analyze its potential mechanism of action. Cell counting kit-8 and lactate dehydrogenase kits were used to detect the viability of colorectal adenocarcinoma Caco-2 cells and lactate dehydrogenase activity, respectively. Apoptosis of the treated cells was detected using flow cytometry. Western blot assay was performed to detect the expression levels of apoptosis-related proteins and p38 MAPK/NF-κB signaling pathway-related proteins. Changes in inflammatory factor secretion in cell supernatants were detected using enzyme-linked immunosorbent assay. Shionone showed no toxic effects on the cells. Shionone enhanced the proliferative activity of lipopolysaccharide-induced Caco-2 cells, decreased lactate dehydrogenase activity, and reduced apoptosis. It also suppressed the secretion of inflammatory factors. Shionone was found to affect the p38 mitogen-activated protein kinase (MAPK)/nuclear factor-kappa B (NF-κB) signaling pathway by decreasing the expression levels of p-p38 and p-p65 proteins and decreasing the ratio of p-p38/p38 and p-p65/p65. Moreover, the p38 mitogen-activated protein kinase agonist, P79350, significantly reversed the effects of shionone on lipopolysaccharide-induced Caco-2 cells, as demonstrated by the promotion of the expression of p-p38 and p-p65, the elevation of the p-p38/p38 and p-p65/p65 ratios, an increase in cell apoptosis, and an increase in inflammatory factor secretion. Shionone alleviated ulcerative colitis through the p38 MAPK/NF-κB signaling pathway, providing a novel therapeutic target for the management of ulcerative colitis.

Graphical Abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

Download references

Funding

No funding was received.

Author information

Authors and Affiliations

Authors

Contributions

PW: conceptualization, formal analysis, project administration, writing, review and editing of the original draft. ZC: supervision, visualization, and writing, review, and editing. YW and XL: investigation, methodology, software, and validation. All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Zhaoping Che.

Ethics declarations

Ethics Approval

Not applicable.

Competing Interests

The authors declare that they have no competing interests.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wei, P., Wang, Y., Li, X. et al. Shionone Relieves Ulcerative Colitis by Regulating the p38 MAPK/NF-κB Pathway. Rev. Bras. Farmacogn. (2024). https://doi.org/10.1007/s43450-024-00552-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s43450-024-00552-5

Keywords

Navigation